Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643170 | 1.00 | MEN1 (0.48) | MEN1KMT2APTGDR2TBXA2RPTGDR | |
| SCHEMBL1643168 | 1.00 | MEN1 (0.48) | MEN1KMT2APTGDR2TBXA2RPTGDR | |
| SCHEMBL1081277 | 0.83 | HTR2A (0.58) | PTGDR2TBXA2RPTGDRKCNQ3KCNQ2 | |
| SCHEMBL152630 | 0.81 | PTGDR2 (0.67) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL152629 | 0.81 | PTGDR2 (0.67) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL152628 | 0.81 | PTGDR2 (0.67) | PTGDR2TBXA2RPTGDR | |
| SCHEMBL1643644 | 0.78 | SCN9A (0.57) | MEN1KMT2APTGDR2TBXA2RPTGDR | |
| SCHEMBL1008863 | 0.76 | PTGDR2 (0.51) | PTGDR2TBXA2RPTGDRKCNQ3KCNQ2 | |
| SCHEMBL1945906 | 0.76 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRPPARGPPARD | |
| SCHEMBL153939 | 0.76 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426449-B2 | Aminoalkylphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8242145-B2 | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098302-A1 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER1 | MEN1 4770/4885KMT2A 4201/4885PTGDR2 2/4885 |
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | MEN1 4863/4885KMT2A 4384/4885PTGDR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.